Tosun NL, et al. - Researchers performed a pilot double-blind, placebo-controlled randomized clinical trial with 216 participants (113 men and 103 women) to assess the efficacy of progesterone (PRO) vs placebo (PBO) for smoking cessation. Among 113 men (18-60 years) PRO was provided to 56 and PBO to 57, and among 103 premenopausal women (18-50 years), PRO was provided to 51 and PBO to 52. Seven-day point prevalence abstinence significantly differed at week 4 among women but not among men. Findings suggest that women may benefit from oral micronized progesterone for smoking cessation.